

Contents

List of Contributors *xiii*

Preface *xv*

List of Abbreviations *xvii*

1	Genomic Strategies for Personalized Cancer Therapy	
	<i>Arkadiusz Z. Dudek, Kate Baxstrom, Sushma Bharadwaj, Anne Blaes, Amit Kulkarni, Emil Lou, Vijeyaluxmy Nehru, Emma Rabinovich, Ardaman Shergill, and Maya Viner</i>	
1.1	Introduction	1
1.1.1	Definition of Precision Medicine in Oncology	1
1.1.2	DNA and RNA Sequencing Techniques	2
1.2	Precision Medicine in Specific Tumors	3
1.2.1	Lung Cancer	3
1.2.1.1	Adenocarcinoma	4
1.2.1.2	Squamous Cell Carcinoma	4
1.2.1.3	Small-Cell Lung Carcinoma (SCLC)	4
1.2.1.4	Epidermal Growth Factor Receptor (EGFR) Mutations	4
1.2.1.5	Anaplastic Lymphoma Kinase (ALK)	5
1.2.1.6	BRAF, ROS1, MET	5
1.2.1.7	KRAS	6
1.2.1.8	Other: RET, NTRK	6
1.2.2	Head and Neck Cancers	6
1.2.2.1	HPV-Positive Cancers	7
1.2.2.2	HPV-Negative Cancers	8
1.2.2.3	Targeting the Epidermal Growth Factor Receptor (EGFR) Pathway	8
1.2.2.4	Thyroid Cancers	8
1.2.2.5	Other Targets	8
1.2.3	Hematological Malignancies	9
1.2.3.1	Lymphoma	9
1.2.3.2	Leukemia	10
1.2.3.3	Myelodysplastic Syndrome	11
1.2.4	Gynecologic Malignancies	11
1.2.4.1	Cervical	11
1.2.4.2	Uterine	11

1.2.4.3	Ovarian	12
1.2.5	Melanoma	13
1.2.6	Gastrointestinal Malignancies	16
1.2.6.1	Gastroesophageal Cancers	17
1.2.6.2	Colorectal Cancers	17
1.2.7	Breast Cancer	19
1.2.7.1	Basal-Like, or Triple Negative Breast Cancer	19
1.2.7.2	Luminal A/B, or Hormone Positive	20
1.2.7.3	HER2 Positive Breast Cancer	20
1.2.7.4	Immunotherapy	20
1.2.7.5	Germline Testing in Breast Cancer	21
1.2.7.6	Conclusion	21
1.2.8	Genitourinary Malignancies	21
1.2.8.1	Prostate Cancer	21
1.2.8.2	Renal Cell Cancer (RCC)	23
1.2.8.3	Urothelial Cancers	23
1.2.9	Pediatric Cancers	24
1.2.9.1	Introduction	24
1.2.9.2	Leukemia and Lymphoma	24
1.2.9.3	Central and Peripheral Nervous System Tumors	25
1.2.9.4	Bone and Soft Tissue Sarcomas	26
1.2.9.5	Other Embryonal Tumors	26
1.2.9.6	Conclusion	27
1.2.10	Cancers of Unknown Primary Origin	27
1.2.10.1	Diagnosis	27
1.2.10.2	Gene Expression Profiling	28
1.2.10.3	Mutational Testing with Next-Generation Sequencing (NGS)	28
1.2.10.4	Treatment	28
1.3	Biomarkers for Immunotherapy of Cancer	28
1.3.1	PD-L1	29
1.3.2	Soluble PD-L1 (sPD-L1)	29
1.3.3	Combined Positive Score (CPS)	30
1.3.4	Tumor Microenvironment	30
1.3.5	Tumor Mutational Burden (TMB)	30
1.3.6	Microsatellite Instability (MSI)	31
1.3.7	MMR Deficiency	31
1.3.8	Peripheral Blood Absolute Neutrophil Count/Absolute Lymphocyte Count	31
1.3.9	Microbiome	31
1.4	Clinical Trial Design in the Era of Precision Oncology	32
1.5	Ethical, Legal, and Social Issues of Precision Oncology	33
1.5.1	Ethical Issues	33
1.5.2	Legal Issues	34
1.5.3	Social Issues	35
1.6	Databases, Data Sharing, and Challenges of Precision Oncology	36
	References	37

2	Blood-Based Biomarkers for the Diagnosis and Prognosis of Cancer	61
	<i>Shreetama Bandyopadhyaya and Chandni C. Mandal</i>	
2.1	Introduction	61
2.2	Importance of Blood-Based Biomarkers	61
2.3	Circulating Proteins as Biomarkers	62
2.4	Circulating Long Non-coding RNAs as Biomarkers	64
2.5	Circulating miRNAs as Biomarkers	65
2.6	Circulating Autoantibodies as Biomarkers	67
2.7	Circulating Tumor DNA as Biomarkers	69
2.8	Metabolites as Biomarkers	70
2.9	Lipids as Biomarkers	72
2.10	Exosomes as Biomarkers	74
2.11	Conclusion	77
	References	77
3	Application of Circulating Cell-free DNA for Personalized Cancer Therapy	83
	<i>Indranil Chattopadhyay</i>	
3.1	Introduction	83
3.2	Drawbacks and Challenges of Invasive Tumor Tissue in Treatment and Diagnosis of Cancer	84
3.3	Importance of Noninvasive Biomarkers in Treatment and Diagnosis of Cancer	84
3.4	Liquid Biopsy: cfDNA and ctDNA	85
3.4.1	Biogenesis of ctDNA: Mechanisms of Release, Characteristics, Quantity, and Quality	85
3.4.2	Role of Preanalytical Factors that Affect cfDNA Measurements	86
3.5	Practical Approach to Estimate ctDNA in Liquid Biopsy	86
3.5.1	Isolation of cfDNA and ctDNA	86
3.5.2	Analysis of ctDNA by Real-Time Quantitative PCR	86
3.5.3	Analysis of ctDNA by Digital PCR (dPCR)	87
3.5.4	Analysis of ctDNA by Beads, Emulsion, Amplification, and Magnetics (BEAMing)	87
3.5.5	Analysis of ctDNA by Next-Generation Sequencing (NGS)	87
3.6	Clinical Application of ctDNA Detection in Various Cancers	88
3.6.1	Clinical Applications of ctDNA in Lung Cancer	88
3.6.2	Clinical Application of ctDNA in Head and Neck Cancer	89
3.6.3	Clinical Utility of Circulating Tumor DNA in Pancreatic Cancer	90
3.6.4	Clinical Utility of Circulating Tumor DNA in Early and Metastatic Breast Cancer	90
3.6.5	Clinical Utility of Circulating Tumor DNA in Colorectal Cancer	91
3.6.6	Clinical Utility of Circulating Tumor DNA in Melanoma	91
3.7	Clinical Utility of Methylation in ctDNA in Personalized Oncology	92
3.8	Conclusion	92
	References	93

4	Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl-2 in Head and Neck Squamous Cell Carcinoma (HNSCC)	99
	<i>Zane Deliu, Ardaman Shergill, Anne Meier, Phylo Thazin Myint, Sarah Khan, Paramjeet Khosla, and Lawrence Feldman</i>	
4.1	Introduction	99
4.2	Epidermal Growth Factor Receptor (EGFR)	99
4.2.1	EGFR Structure and Ligands	99
4.2.2	Physiology	100
4.2.3	EGFR Expression and Genetic Changes	100
4.2.3.1	EGFR Expression in HNSCC	100
4.2.3.2	Normal Adjacent Oral Mucosa and Pre-malignant Lesions	101
4.2.4	EGFR Genetic Changes: Gene Copy Numbers, Amplifications, and Mutations in HNSCC	101
4.2.4.1	Association of EGFR Expression or Genetic Changes with HPV Infection	101
4.2.5	EGFR as a Prognostic and Predictive Marker	102
4.2.5.1	EGFR as a Prognostic Marker	102
4.2.5.2	EGFR as a Predictive Marker	102
4.2.6	Future Perspectives	103
4.2.6.1	EGFR in Immuno-SPECT or PET Imaging	103
4.2.6.2	Molecular Profiling for Precision Medicine	104
4.3	TP53 Mutations in Head and Neck Cancer	104
4.3.1	Pathogenesis and Prevalence	104
4.3.2	Risk Factors	104
4.3.3	TP53 Structure and Physiology	105
4.3.3.1	TP53 Structure	105
4.3.3.2	TP53 as a Tumor Suppressor Gene	105
4.3.4	TP53 Gain of Function Properties	105
4.3.5	TP53 as a Prognostic and Predictive Marker	106
4.3.6	Therapeutic Strategies Targeting TP53	106
4.4	P16 and Cyclin D1 Mutations in Head and Neck Cancer	107
4.4.1	Cyclin D1	107
4.4.2	P16	108
4.5	Bcl-2 Mutations in Head and Neck Cancer	109
4.5.1	Bcl-2	109
4.5.1.1	Physiological Role of Bcl-2	109
4.5.2	Bcl-2 Family of Proteins	109
4.5.3	Significance of Bcl-2 Overexpression	110
4.5.4	Association with Chemoresistance and Radioresistance	111
4.5.5	Role of Bcl-2 as a Marker of Prognosis	111
4.5.6	Chemotherapeutics Targeting Bcl-2	112
4.5.7	Bcl-2 Summary	113
4.6	Conclusion	113
	References	114

5	Immunotherapy and Cancer	133
	<i>Maaly Bassiony, Adedoyin Victoria Aluko, and James A. Radosevich</i>	
5.1	Introduction	133
5.2	What Is Cancer Immunotherapy?	134
5.3	How Does Immunotherapy Work?	135
5.4	Timing of Immunotherapy	135
5.5	Combination Immunotherapy	136
5.6	Side Effects of Immunotherapy	137
5.7	Types of Cancer Immunotherapy Treatments	137
5.7.1	Immune Checkpoint Inhibitors	137
5.7.2	Monoclonal Antibodies and Tumor-Agnostic Therapies	138
5.7.3	Adoptive T Cell Therapy	138
5.8	Cancer Vaccines	139
5.9	Oncolytic Viral Immunotherapy (OVIs)	140
5.10	Non-specific Immunotherapies	141
5.11	Immunotherapy by Cancer Type	141
5.11.1	Skin Cancer	141
5.11.2	Lung Cancer	142
5.11.3	Breast Cancer	142
5.11.4	Kidney and Prostate Cancers	143
5.11.5	Brain Cancer	145
5.11.6	Colorectal Cancer	146
5.11.7	Bladder Cancer	147
5.11.8	Cervical Cancer	147
5.11.9	Leukemia	147
5.11.10	Liver Cancer	148
5.12	Proven Studies	150
5.13	Cancer Immunity Pathway	150
5.14	Recent Developments in Immunotherapy	150
5.15	Neoantigens for Cancer Immunotherapy	151
5.16	Discussion	152
	References	153
6	Predictive and Prognostic Markers for Cancer Medicine	157
	<i>Elif Zeynep Yilmaz and Ebru Esin Yoruker</i>	
6.1	Introduction	157
6.2	Historical Development of Cancer Markers	157
6.3	Characteristics of the Ideal Cancer Markers	158
6.3.1	Ideal Source of Cancer Markers	159
6.3.2	Kinetics of Cancer Markers	162
6.3.3	Sensitivity and Specificity for Evaluation of Cancer Markers	163
6.4	Utilization of Cancer Markers in Most Common Cancers	163
6.4.1	Colorectal Cancer	166
6.4.1.1	CEA	166

- 6.4.1.2 KRAS/NRAS 167
- 6.4.1.3 MSI 168
- 6.4.1.4 PD-1/PD – L1 168
- 6.4.1.5 BRAF 169
- 6.4.1.6 Oncotype DX Colon Cancer Test 169
- 6.4.1.7 ColoPrint 169
- 6.4.1.8 CTC 169
- 6.4.2 Breast Cancer 169
 - 6.4.2.1 ER/PR 170
 - 6.4.2.2 HER2 171
 - 6.4.2.3 Oncotype DX 171
 - 6.4.2.4 MammaPrint 171
 - 6.4.2.5 uPA/PAI-1 172
- 6.4.3 Ovarian Cancer 172
- 6.4.4 Lung Cancer 172
 - 6.4.4.1 EGFR 173
 - 6.4.4.2 ALK Rearrangements 173
 - 6.4.4.3 ROS1 Rearrangements 174
- 6.4.5 Urological Cancers 174
 - 6.4.5.1 Prostate Cancer 174
 - 6.4.5.2 Renal Cancer 175
- 6.5 Classification and Techniques for Studying of Cancer Markers 176
 - 6.5.1 Circulating Tumor Cells as Cancer Markers 176
 - 6.5.2 DNA-Based Cancer Markers 177
 - 6.5.2.1 Microsatellite Alterations 177
 - 6.5.2.2 cfDNA Integrity 177
 - 6.5.2.3 DNA Methylation 178
 - 6.5.2.4 Mutations and Single Nucleotide Polymorphisms (SNPs) 178
 - 6.5.3 RNA-Based Tumor Markers 180
 - 6.5.3.1 mRNAs 180
 - 6.5.3.2 Noncoding RNAs 180
 - 6.5.4 Protein-Based Tumor Markers 181
- 6.6 Clinical Validation of Cancer Markers 185
- 6.7 Conclusions and Future Perspectives 186
- References 187

7 Dual Energy Imaging in Precision Radiation Therapy 203

John C. Roeske, Maksat Haytmyradov, Roberto Cassetta, and Murat Surucu

- 7.1 Introduction and Overview 203
- 7.2 Historical Perspective 203
 - 7.2.1 X-Ray Production 204
 - 7.2.2 X-Ray Interactions in Matter 205
 - 7.2.3 Planar Image Formation 205
 - 7.2.4 Computed Tomography 206
 - 7.2.5 X-Ray Imaging in Radiation Oncology 207

7.2.6	Dual Energy Imaging in Radiation Therapy	207
7.3	Planar Dual Energy Imaging	208
7.3.1	Theory	209
7.3.2	Planar Dual Energy Imaging Methods	210
7.3.3	Applications in Radiation Therapy	210
7.3.3.1	Image-Guided Radiation Therapy	211
7.3.3.2	Markerless Tumor Tracking	211
7.3.3.3	Megavoltage Dual Energy Imaging	214
7.4	Dual Energy Computed Tomography	214
7.4.1	Theory	215
7.4.2	Dual Energy Scanning Methods	216
7.4.3	Applications in Radiation Therapy	218
7.4.3.1	Brachytherapy Planning	218
7.4.3.2	Proton Planning	218
7.4.3.3	Normal Tissue Segmentation	220
7.4.3.4	Assessment of Therapy Response	221
7.4.3.5	Dual Energy Cone Beam Computed Tomography	222
7.5	Summary and Future Directions	222
	Acknowledgement	223
	References	224
8	The Role of Big Data in Personalized Medicine	229
	<i>Jean-Emmanuel Bibault and Lei Xing</i>	
8.1	Introduction	229
8.2	The Concept of Big Data and the Specificities of Healthcare	230
8.2.1	Volume: How Big Is Big Data?	230
8.2.2	Variety: Where Does Big Data Come from?	231
8.2.3	Velocity: How Fast Is Big Data Generated and Interpreted?	232
8.2.4	Variability: How Does Big Data Change?	232
8.2.5	Veracity: How Accurate Is Big Data?	232
8.2.6	Value: Why Is Big Data Important?	232
8.3	Sources of Data	233
8.3.1	Genomics, Epigenomics, and Transcriptomics	233
8.3.2	Proteomics and Metabolomics	234
8.3.3	Medical Imaging and Radiomics	235
8.3.4	Clinical Informatics	236
8.4	Big Data Analytical Techniques	236
8.4.1	Machine Learning	236
8.4.2	Deep Learning	237
8.4.3	Natural Language Processing	238
8.5	Challenges in Big Data Analytics	239
8.5.1	Implementing a Big Data Approach	239
8.5.2	Developing an Information-Sharing Culture	239
8.5.3	Security Measures	240
8.5.4	Ethics in Big Data Analysis	240

8.5.4.1 Consent in the Era of Big Data 240

8.5.4.2 Privacy 240

8.5.4.3 Anonymization 241

8.5.4.4 Ownership 241

References 241

Index 249